Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,626 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Genetics Clear all

Conditions: Sarcoma, Neuroblastoma, Wilm's Tumor
Interventions: Tumor lysate-pulsed dendritic cell (DC) vaccine, Hematopoietic stem cell transplantation (HSCT); Biological · Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Up to 30 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: NF2-related Schwannomatosis
Interventions: Auto-captioning Glasses; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epilepsy, Tuberous Sclerosis Complex, Focal Cortical Dysplasia
Interventions: Everolimus; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 2 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Schwannoma, Vestibular, Neurofibromatosis 2, Meningioma
Interventions: Not listed
Lead sponsor: House Ear Institute; Other
Eligibility: 5 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Carcinoma, Basal Cell, Recurrent Skin Cancer, Skin Neoplasms, Basal Cell Nevus Syndrome
Interventions: Buparlisib, Sonidegib; Drug
Lead sponsor: Anne Chang; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pediatric Solid Tumor, Sarcoma, Neuroblastoma, Wilms Tumor
Interventions: Not listed
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Up to 30 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 5
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more

Conditions: Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: counseling intervention, educational intervention, survey administration, psychosocial assessment and care, supportive care; Other · Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 8 Years to 120 Years · Female only
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts

Conditions: Fanconi Anemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: biologic sample preservation procedure, biopsy; Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 1 Year to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Neurofibromatosis 1
Interventions: Everolimus; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia, MEN1
Interventions: 68Ga-Dotatate, 18F-DOPA; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Months and older
Enrollment: 1,553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions: docetaxel, thalidomide; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older · Male only
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck Squamous Cell Carcinoma, Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Interventions: Aspirin, Paclitaxel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Specific Advanced Solid Tumors
Interventions: ACR-2316; Drug
Lead sponsor: Acrivon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 15
States / cities: Phoenix, Arizona • Beverly Hills, California • Newport Beach, California + 12 more

Conditions: Breast Neoplasms, Ovarian Neoplasms
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasm
Interventions: Crizotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 0 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 17
States / cities: Aurora, Colorado • St. Petersburg, Florida • Atlanta, Georgia + 9 more

Conditions: Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma, Wilms Tumor, Yolk Sac Tumor
Interventions: CARE T cells; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2042
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Eyelid Diseases, Ptosis, Eyelid, Blepharoptosis, Dermatochalasis, Ectropion, Entropion, Eyelid Tumor, Skin Cancer, Eyelid, Floppy Eyelid Syndrome
Interventions: Telemedicine follow-up; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Colorectal Adenoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 937 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2020
U.S. locations: 3
States / cities: San Diego, California • Bethesda, Maryland • Portsmouth, Virginia

Conditions: Hereditary Breast and Ovarian Cancer
Interventions: BRCA-Gist; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Alexandria, Virginia • Richmond, Virginia

Conditions: Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Interventions: ASN-002; Biological
Lead sponsor: Ascend Biopharmaceuticals Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin ER, Metformin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Interventions: tucatinib, trastuzumab, ramucirumab, paclitaxel, tucatinib placebo, trastuzumab placebo; Drug · Other
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more

Conditions: Cancer
Interventions: Broad gene panel for young adult cancers, Standard; Genetic
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 40 Years
Enrollment: 749 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia, Myeloid, Acute
Interventions: Biospecimen samples; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Search by objective public record fields.

A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation

Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis

A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

NF2 Natural History Consortium

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

iCAT for Recurrent/Refractory/HR Solid Tumors

Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

Tissue Sample Collection From Patients With Fanconi Anemia

Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T

Studies of Elevated Parathyroid Activity

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma

Study of ACR-2316 in Specific Advanced Solid Tumors

Outcomes of Education and Counseling for BRCA1 Testing

Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Telemedicine Follow-up for Routine, Low-Risk Oculoplastic Surgery

Colorectal Neoplasia Screening w Colonoscopy in Asymptomatic Women at Regional Navy/Army Medical Ctrs: The CONCeRN Trial

Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Polycystic Ovary Syndrome Genetics and Treatment Response

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

Genetic Testing in Young Adults With Cancer Study

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML